| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-540SS | |||
| Azide and BSA Free | NBP2-80677 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-76701SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22115SS | |||
| Azide and BSA Free | NBP2-80618 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-07035SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-22114SS | |||
| Azide and BSA Free | NBP2-80827 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-724SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP1-80289-20ul | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-77477SS | |||
| Azide and BSA Free | NBP2-80624 | |||
![Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Intracellular-NB200-540-img0005.jpg "<b>Biological Strategies Validation. </b>Flow (Intracellular): Complement C3 Antibody (11H9) [NB200-540] - An intracellular stain was performed on RAW 246.7 cells with Complement C3 (11H9-3-2) antibody NB200-540 (blue) and a matched isotype control NBP2-31382 (orange). Cells were either treated with 3uM Monensin for 3 hours to block the secretion of Complement C3 (B) or grown in normal media (A). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: Complement C3 Antibody (11H9) [NB200-540] - C3 protein fragments deposited on kidney cells of MPL-lpr mouse. Staining with antibody 11H9. Glomerular staining pattern. Fixation in 4% paraformaldehyde in PBS pH 7.4. Vibratome sections of 4 um. Pretreated with 3% hydrogen peroxide for 20 min to quench endogenous peroxidases. Microwaved in antigen unmasking solution for 2-5 minutes as antigen retrieval.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunocytochemistry-Immunofluorescence-NB200-540-img0002.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse liver using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. Weak but distinct membrane-cytoplasmic immunopositivity was observed in hepatocytes and few cells developed punctate membrane staining.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0004.jpg)
![Flow Cytometry: Complement C3 Antibody (11H9) [NB200-540] - Left panel: FMO, Middle panel: No primary antibody control, Right panel: sample. Day 6 murine mammary tumors processed and stained for analysis with flow cytometry. The C3b+ population of CD45+ cells is what the gate in each sample is exhibiting. WB image submitted by a verified customer review.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Flow-Cytometry-NB200-540-img0006.jpg)
![Immunohistochemistry-Paraffin: Complement C3 Antibody (11H9) [NB200-540] - Complement C3 protein in a FFPE tissue section of mouse lymph node using 1:100 dilution of Complement C3 antibody (clone 11H9) NB200-540. This representative photomicrograph shows a membrane-cytoplasmic immunopositivity in non-germinal center cells, and few cells developed an intense staining for this target protein.](http://images.novusbio.com/fullsize/Complement-C3-Antibody-11H9-Immunohistochemistry-Paraffin-NB200-540-img0003.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0016.jpg "<b>Biological Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - In vitro nephrotoxicity assessment of kidney spheroids. Western blotting analysis of kidney injury markers in kidney spheroids after treatment with 20 uM cisplatin (CPT) or 50 uM cisplatin cyclosporin A (CSA). All data are shown as the means +/- s.e.m. *p < 0.05 compared with control by unpaired Student's t-test. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (www.nature.com/articles/s41598-019-53855-2) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Analysis of human uterus tissue using anti-TIM-1 antibody (3809) at 10 ug/ml.Tissue was fixed with formaldehyde and blocked with 10% serum for 1 h at RT; antigen retrieval was by heat mediation with a citrate buffer (pH6). Samples were incubated with primary antibody overnight at 4 C. A goat anti-rabbit IgG H&L (HRP)at 1/250 was used as secondary. Counter stained with Hematoxylin.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Immunohistochemistry-Paraffin-NBP1-76701-img0013.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of NIH/3T3 cell lysates. Antibodies: TIM-1 3809 (8 ug/mL), overnight incubation at 4 C in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0010.jpg)
![<b>Independent Antibodies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - Loading: 15 ug of lysates per lane. Antibodies: TIM-1 3809 (8 ug/mL), TIM-13811 (1 ug/mL), beta-actin (1 ug/mL), and GAPDH (0.02 ug/mL), overnightincubation at 4C (3809) or 1h incubation at RT in 5% NFDM/TBST. Secondary:Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0012.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - TIM-1/KIM-1/HAVCR Antibody [NBP1-76701] - HeLa cells were transfected with control siRNAs (lane 1) or TIM-1 siRNAs (lane 2) Loading: 15 ug of HeLa whole cell lysates per lane. Antibodies: 3809 (8 ug/mL), 1 hincubation at RT in 5% NFDM/TBST. Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/TIM-1-KIM-1-HAVCR-Antibody-Western-Blot-NBP1-76701-img0015.jpg)
![Western Blot: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Figure 1 Western Blot Validation in Human Cell LinesLoading: 15 u of lysates per lane.Antibodies: TIM-1 (8 u/mL), overnight incubation at 4; C in 5% NFDM/TBST.Secondary: Goat anti-rabbit IgG HRP conjugate at 1:10000 dilution.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-2711202420171718.gif)
![Immunocytochemistry/ Immunofluorescence: TIM-1/KIM-1/HAVCR Antibody - BSA Free [NBP1-76701] - Validation of TIM-1/KIM-1/HAVCR in Human Uterus Cells. Immunofluorescent analysis of 4% paraformaldehyde-fixed human uterus cells labeling TIM-1/KIM-1/HAVCR with at 20 ug/mL, followed by goat anti-rabbit IgG secondary antibody at 1/500 dilution (red). Image showing both membrane and cytoplasmic staining on human uterus cells.](http://images.novusbio.com/fullsize/nbp1-76701_rabbit-polyclonal-tim-1-kim-1-havcr-antibody-271120241937768.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0003.jpg "Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mouse mAb against A549 (1), HeLa (2), Raw264.7 (3), L1210 (4), C6 (5), and COS-7 (6) cell lysates.")
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of HepG2 cells using A) MCP1 mAb (green), DRAQ5 fluorescent DNA dye (blue), and Actin filaments have been labeled with Alexa Fluor-555 phalloidin (red). B) Staining without MCP1 mAb](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0011.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - HER2 activates NF-kB and upregulates CCL2. MGs from FVB wild-type and 22-week-old MMTV-HER2 mice stained against CCL2, HER2, and CCR2. Bars: 25 um. Inset, CCR2 signal, zoom factor 1x; full image in Supplementary Fig. 5i. CCL2 intensity was quantified using ROI tool in Metamorph (Supplementary Fig. 5h). Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0009.jpg)
![Flow Cytometry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of A549 cells using MCP1 mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Flow-Cytometry-NBP2-22115-img0004.jpg)
![Western Blot: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis using MCP1 mAb against human MCP1 (AA: 1-99) recombinant protein. (Expected MW is 36.5 kDa)](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Western-Blot-NBP2-22115-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - CCL2 staining in acini cultures from MMTV-HER2 MGs (20-24 weeks) grown for 5 days and then DMSO-treated (vehicle control, e), 1uM lapatinib (f) or 1 uM IKKi compound A (g) for 24 hrs. Bar: 25 um. Image collected and cropped by CiteAb from the following publication (//www.nature.com/articles/s41467-017-02481-5), licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunocytochemistry-Immunofluorescence-NBP2-22115-img0010.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Organotypic specimens were treated with anti-LIF for 72 h and then cultured with PBMCs for 24 h. CXCL9 and CCL2 mRNA expression levels are shown. Representative images (patient 4, 5, 6) of CFSE-stained PBMCs into Matrigel containing GBM specimens and IF of the indicated factors in organotypic tissues are displayed. Bars represent quantification of five different fields of each condition. Data are presented as mean +/- SD. Scale bar, 20 um. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-NBP2-22115-img0012.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Analysis of paraffin-embedded liver cancer tissues using MCP1 mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-Immunohistochemistry-Paraffin-NBP2-22115-img0007.jpg)
![ELISA: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Red: Control Antigen (100ng), Purple: Antigen (10ng), Green: Antigen (50ng), Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-2D8-BSA-Free-ELISA-NBP2-22115-img0001.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - Expression patterns of CCL2 & CCR2 in unwounded & wounded corneas of WT & MMP12 KO mice. (A) Immunofluorescence of CCL2 chemokine & (B) its receptor CCR2 in unwounded & chemically wounded (2-days after injury) WT & Mmp12−/− mouse corneas. Control images represent mouse corneas stained with secondary antibody only & without primary antibody. Nuclei were visualized by staining with DAPI (blue). Scale bars: 50 µm. A magnified image of a wounded WT cornea shows perinuclear expression of CCL2 (orange box). CCL2 staining was visualized in epithelial, stromal, & endothelial layers of wounded WT & Mmp12−/− corneas. CCR2 staining was visualized in epithelial & stromal layers of unwounded & wounded WT & Mmp12−/− corneas. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31399604), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202415384136.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF represses CXCL9 through epigenetic silencing. a, b qRT-PCR analysis of the indicated genes in BMDMs. BMDMs were pre-incubated with 20 ng/ml LIF for 72 h & then stimulated with 5 ng/ml IFN gamma or 10 μg/ml IL4 during 6 h (a) or with 0.1, 0.5, 1 & 5 ng/ml IFN gamma for 24 h (b). c CXCL9 ELISA from BMDMs pre-incubated with 20 ng/ml LIF & then stimulated with 0.1 ng/ml IFN gamma for 24 h. d CXCL9 ELISA from human CD11b+sorted cells (77% CD11b+ CD14+, see Supplementary Fig. 7b, c) from human GBM cultured with 20 ng/ml LIF for 72 h & then with 0.1 ng/ml IFN gamma for 24 h. e ChIP of Tri-methyl-histone H3 (H3K27me3), EZH2 & acetyl-histone4 (H4ac) was performed in BMDMs treated with 20 ng/ml LIF for 72 h. Scheme shows the analysed CXCL9 promoter region. Representative data are presented as mean ± SD. f Representative images of IF of the indicated markers in human GBM organotypic slices (patients 1, 2, 3) incubated with 10 μg/ml anti-LIF for 3 days. Scale bar, 20 μm. (see Supplementary Fig. 8). Bottom, percentage of double positive cells relative to Iba1+ cells & percentage of CXCL9+ cells relative to the total number of cells. Data are mean of all patients ± SEM. Statistical analyses by Student’s t-test or Mann–Whitney T-test. *P < 0.05, **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-3102024161360.jpg)
![Immunohistochemistry: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-310202416114760.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody (2D8) - BSA Free [NBP2-22115] - LIF regulates CXCL9, CCL2, CD206, & CD163 in TAMs. a Differential expression analysis of isolated CD11b+ cells from anti-LIF treated ID8 mice vs. control. Volcano plot representing the genes significantly (Q-value < 0.1) overexpressed (brown) & significantly underexpressed (turquoise). Heatmap representing the expression values of the indicated genes, each column represents a sample & each row a gene. The last column represents the log2 fold change (log2 FC) of gene expression. b mRNA expression for the indicated genes in isolated CD11b+ cells from anti-LIF treated or untreated ID8 & GL261N tumors. c Percentage & mean fluorescence intensity (MFI) of CCL2 & CXCL9 in TAMs (CD11b+ Ly6G− Ly6C−) from anti-LIF treated or untreated GL261N tumors. d Representative IF images of Iba1 & the indicated markers stainings of GL261N tumors (see Supplementary Fig. 4). Scale bar, 20 μm. Bottom, percentage of double positive cells relative to the TAM marker positive cells. CXCL9 quantification is relative to the total number of cells. e Tumor growth of GL261N in WT, CXCL9−/−, & CCL2−/− mice or mice treated with the indicated antibodies is shown as total flux (p/s). f Fold change (FC) of tumor infiltrating CD8+ T cells in the indicated treatments. Data are mean ± SEM. g, h Representative IHC of the indicated markers from 20 GBM tumors. The degree of staining was quantified using H-score method. Correlations between LIF & CCL2, CD206, CD163, & CXCL9 with the R-squared coefficients (R2) were calculated (h). Statistical analyses by Mann–Whitney T-test. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001 Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31186412), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp2-22115_mouse-monoclonal-ccl2-mcp1-antibody-2d8-31020241613617.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Western blot for MCP-1 protein was analyzed from the ox-LDL-stimulated THP-1 cells. B-actin was used as loading control (D-I). Scale bar: 20 um. Bar graph indicates the mean +/- SD (n = 3). *P < 0.05 and **P < 0.01 vs. Cont group (0 ug/mL of ox-LDL). Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0014.jpg "<b>Biological Strategies Validation. </b>Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Western blot for MCP-1 protein was analyzed from the ox-LDL-stimulated THP-1 cells. B-actin was used as loading control (D-I). Scale bar: 20 um. Bar graph indicates the mean +/- SD (n = 3). *P < 0.05 and **P < 0.01 vs. Cont group (0 ug/mL of ox-LDL). Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.")
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody [NBP1-07035] - IHC analysis of a formalin-fixed paraffin-embedded (FFPE) human breast carcinoma tissue section using 1:1000 dilution of CCL2/MCP1 antibody (NBP1-07035) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of CCL2 antigen in the cancer cells, stromal cells as well as the endothelial cells. The stroma itself showed a weak immunopositivity for CCL2. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunohistochemistry-Paraffin-NBP1-07035-img0007.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - Inhibition of SIRT1 using EX-527 or SIRT1 siRNA transfection enhanced MCP-1 expression and foam cell formationHuman THP-1 macrophages were pretreated with EX-527 (2 uM, for 2 hrs) or SIRT1 siRNA (20 uM, for 24 hrs), and then exposed to 80 i1/4g/mL of ox-LDL for an additional 24 hrs. Western blot for SIRT1 and MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. I2-actin was used as loading control. Image collected and cropped by Citeab from the following publication (SIRT1 inhibition promotes atherosclerosis through impaired autophagy. Oncotarget (2017)) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0013.jpg)
![Immunocytochemistry/Immunofluorescence: CCL2/MCP1 Antibody [NBP1-07035] - MCP1 antibody was tested in HeLa cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-07035-img0006.jpg)
![Immunohistochemistry-Paraffin: CCL2/MCP1 Antibody [NBP1-07035] - IHC analysis of a formalin-fixed paraffin-embedded (FFPE) human breast carcinoma tissue section using 1:1000 dilution of CCL2/MCP1 antibody (NBP1-07035) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). This antibody generated a diffused cytoplasmic staining of CCL2 antigen in the cancer cells, stromal cells as well as the endothelial cells. The stroma itself showed a weak immunopositivity for CCL2. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Immunohistochemistry-Paraffin-NBP1-07035-img0008.jpg)
![Western Blot: CCL2/MCP1 Antibody [NBP1-07035] - CCL2 expression level was evaluated in control group and aLAG-3 group.](http://images.novusbio.com/fullsize/CCL2-MCP1-Antibody-Western-Blot-NBP1-07035-img0009.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Ox-LDL induced macrophage foam cell formation, SIRT1 inhibition, autophagy impairment, & MCP-1 production in THP-1 cellsHuman THP-1 macrophages were exposed to 0, 20, 40, 60, & 80 μg/mL of ox-LDL for 24 hrs. Treated cells were photographed using light microscopy (A). The THP-1 macrophage-derived foam cell formation was determined using ORO staining method (B) & (C). Western blot for SIRT1, LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (D-I). Scale bar: 20 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group (0 μg/mL of ox-LDL). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202415304238.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of autophagy with 3-MA led to increased foam cell formation & MCP-1 productionHuman THP-1 macrophages were pretreated with 3-MA (5 μM) for 2 hrs, & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot for LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-E). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (F-G). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group; #P < 0.05 & ##P < 0.01 vs. 3-MA group; &P < 0.05 & &&P < 0.01 represent significant differences between ox-LDL group & 3-MA+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202415384154.jpg)
![Immunocytochemistry/ Immunofluorescence: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - CCL2-ir cellular distribution in ependymal layers attached to the CC. A, B CCL2-ir (CCL2 panels, arrows) & GFAP (GFAP panels, arrowheads) double immunostained structures (Merged panels, arrow-arrowheads) are seen inlaid in the ependymal layers attached to the CC in both saline & LPS injected mice. C A CCL2-ir & Iba-1 double labeled soma (Merged, arrow-arrowhead) is seen at a corner of lateral ventricle, which seems be just next to an invaginated choroid plexus between the CC & basal ganglion (framed areas & insets). D, E Hyper-ramified & amoeba like Iba-1 labeled cells (Iba-1 panel, opened arrowheads) are observed in the CC of LPS injected mice, indicating their activated states. The CCL2-ir & Iba-1 double labeled structures are also regarded in the ependymal layers (Merged, arrow-arrowheads). Scare bar = 100 µm in all A– E Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35354428), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416161849.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of autophagy using Atg5 siRNA aggravated foam cell formation & MCP-1 expressionHuman THP-1 macrophages were pretreated with Atg5 siRNA (20 μM) for 24 hrs, & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot forAtg5, LC3, Beclin1, p62, & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-F) & (I). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (G) & (H). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. NC siRNA group; #P < 0.05 & ##P < 0.01 vs. Atg5 siRNA group; &P < 0.05 & &&P < 0.01 represent significant differences between NC siRNA+ox-LDL group & Atg5 siRNA+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-31020241618266.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Inhibition of SIRT1 using EX-527 or SIRT1 siRNA transfection enhanced MCP-1 expression & foam cell formationHuman THP-1 macrophages were pretreated with EX-527 (2 μM, for 2 hrs) or SIRT1 siRNA (20 μM, for 24 hrs), & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. Western blot for SIRT1 & MCP-1 proteins were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (A-C) & (F-H). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (D-E) & (I-J). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. Cont group (NC siRNA group); #P < 0.05 & ##P < 0.01 vs. EX-527 group (SIRT1 siRNA group); &P < 0.05 & &&P < 0.01 represent significant differences between ox-LDL group (NC siRNA+ox-LDL group) & EX-527+ox-LDL group (SIRT1 siRNA+ox-LDL group). Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416171476.jpg)
![Western Blot: CCL2/MCP1 Antibody - BSA Free [NBP1-07035] - Overexpression of SIRT1 using adenoviral transfection reversed ox-LDL-induced macrophage foam cell formation & autophagy impairment in THP-1 cellsHuman THP-1 macrophages were transfected by SIRT1 over-expressing adenovirus (HBAD-SIRT1) or NC adenovirus (HBAD-GFP) for 24 hrs & then exposed to 80 μg/mL of ox-LDL for an additional 24 hrs. The transfected THP-1 cells were observed using an inverted fluorescence microscope (A) & then were harvested for transfection efficiency analysis by Western blot method (B). THP-1 macrophage-derived foam cell formation was determined using ORO staining method (C) & (D). Western blot for LC3, Beclin1, p62, & Atg5 proteins & immunoprecipitation for acetyl-Lys Atg5 were analyzed from the ox-LDL-stimulated THP-1 cells. beta -actin was used as loading control (E-L). Scale bar: 40 μm. Bar graph indicates the mean ± SD (n = 3). *P < 0.05 & **P < 0.01 vs. HBAD-GFP group; #P < 0.05 & ##P < 0.01 vs. HBAD-SIRT1 group; &P < 0.05 & &&P < 0.01 represent significant differences between HBAD-GFP+ox-LDL group & HBAD-SIRT1+ox-LDL group. Image collected & cropped by CiteAb from the following publication (//www.oncotarget.com/lookup/doi/10.18632/oncotarget.17691), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-07035_rabbit-polyclonal-ccl2-mcp1-antibody-310202416163742.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0002.jpg "Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis using TGF beta 1 mAb against human LAP (TGF-beta 1) recombinant protein. (Expected MW is 41 kDa)")
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lymphoid tissue tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0005.jpg)
![Flow Cytometry: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Flow cytometric analysis of A549 cells using LAP (TGF-beta 1) mouse mAb (green) and negative control (red).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Flow-Cytometry-NBP2-22114-img0003.jpg)
![Western Blot: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Western blot analysis of human stomach tissue (A) and human small intestine tissue (B) using TGF beta 1 antibody (NBP2-22114) at 2 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Western-Blot-NBP2-22114-img0007.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Human tonsil. Image from verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0006.jpg)
![Immunohistochemistry-Paraffin: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Immunohistochemical analysis of paraffin-embedded lung cancer tissues using LAP (TGF-beta 1) mouse mAb with DAB staining.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-Immunohistochemistry-Paraffin-NBP2-22114-img0004.jpg)
![ELISA: LAP (TGF-beta 1) Antibody (7F6) [NBP2-22114] - Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng).](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-7F6-ELISA-NBP2-22114-img0001.jpg)
![Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - ACE-2 staining in immersion fixed paraffin-embedded sections of human lung normal (left) and lung cancer tissue (right) using Mouse Anti-Human ACE-2 (SN0754) Monoclonal Antibody (Catalog # NBP2-67692) at 10 ug/ml for 1 hour at room temperature followed by incubation with Goat anti-Mouse IgG Secondary Antibody.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunohistochemistry-Paraffin-NBP2-67692-img0009.jpg "Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - ACE-2 staining in immersion fixed paraffin-embedded sections of human lung normal (left) and lung cancer tissue (right) using Mouse Anti-Human ACE-2 (SN0754) Monoclonal Antibody (Catalog # NBP2-67692) at 10 ug/ml for 1 hour at room temperature followed by incubation with Goat anti-Mouse IgG Secondary Antibody.")
![Western Blot: ACE-2 Antibody (SN0754) [NBP2-67692] - Analysis of ACE2 on different lysates. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in PBS for 1 hour at room temperature. The primary antibody (1/500) was used in 5% BSA at room temperature for 2 hours. Goat Anti-Rabbit IgG - HRP Secondary Antibody at 1:5,000 dilution was used for 1 hour at room temperature. Positive control: Lane 1: human kidney tissue lysateLane 2: human small intestine tissue lysate](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Western-Blot-NBP2-67692-img0011.jpg)
![Immunocytochemistry/Immunofluorescence: ACE-2 Antibody (SN0754) [NBP2-67692] - Staining ACE2 in MCF-7 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunocytochemistry-Immunofluorescence-NBP2-67692-img0003.jpg)
![Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - ACE-2 staining in paraffin-embedded sections of hamster lung tissue using Rabbit Anti-Human ACE-2 (SN0754) Monoclonal Antibody (Catalog # NBP2-67692) at 3 ug/ml overnight at 4 degrees C. Detection kit: VC003. Counterstain: Hematoxylin. Localization: respiratory bronchioles.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunohistochemistry-Paraffin-NBP2-67692-img0010.jpg)
![Western Blot: ACE-2 Antibody (SN0754) [NBP2-67692] - Western blot analysis of ACE-2 on Hamster testis (1) and stomach (2) tissue lysates using anti-ACE-2 antibody at 1/1,000 dilution.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Western-Blot-NBP2-67692-img0008.jpg)
![Immunocytochemistry/Immunofluorescence: ACE-2 Antibody (SN0754) [NBP2-67692] - Staining ACE2 in 293 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunocytochemistry-Immunofluorescence-NBP2-67692-img0001.jpg)
![Immunocytochemistry/Immunofluorescence: ACE-2 Antibody (SN0754) [NBP2-67692] - Staining ACE2 in HepG2 cells (green). The nuclear counter stain is DAPI (blue). Cells were fixed in paraformaldehyde, permeabilised with 0.25% Triton X100/PBS.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunocytochemistry-Immunofluorescence-NBP2-67692-img0002.jpg)
![Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - Analysis of paraffin-embedded human breast carcinoma tissue using anti-ACE2 antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunohistochemistry-Paraffin-NBP2-67692-img0004.jpg)
![Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - Analysis of paraffin-embedded human kidney tissue using anti-ACE2 antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunohistochemistry-Paraffin-NBP2-67692-img0005.jpg)
![Immunohistochemistry-Paraffin: ACE-2 Antibody (SN0754) [NBP2-67692] - Analysis of paraffin-embedded mouse kidney tissue using anti-ACE2 antibody. Counter stained with hematoxylin.](http://images.novusbio.com/fullsize/ACE-2-Antibody-SN0754-Immunohistochemistry-Paraffin-NBP2-67692-img0006.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0007.jpg "Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha and ER beta Antagonists on NE Regulation of VMN nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS) - Panel 2A,F(5, 12)=12.67,p<.0001 - protein expression. Data depict mean normalized protein optical density (O.D.) values+/-SEMfor groups of rats (n=6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p<.05; **p<.01; ***p<.001. Image collected and cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668/) licensed under a CC-BY license.")
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cerebellum at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0004.jpg)
![Western Blot: nNOS Antibody [NBP1-39681]](http://images.novusbio.com/fullsize/nNOS-Antibody-Western-Blot-NBP1-39681-img0006.jpg)
![Immunohistochemistry-Paraffin: nNOS Antibody [NBP1-39681] - Analysis of anti-nNOS / NOS1 antibody with human brain, cortex at concentration 5 ug/ml.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NBP1-39681-img0003.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Laser-Catapult Microdissection of Immunolabeled ventromedial hypothalamic nucleus (VMN) GABA or Nitrergic Neurons: Western Blot Confirmation of Accuracy of Immunocytochemical Identification of Neurotransmitter Phenotype. VMN neurons were identified in situ for glutamate decarboxylase65/67 (GAD65/67)- (top row, Panel 1A) or neuronal nitric oxide (nNOS)-immunoreactivity (-ir) (bottom row, Panel 2A); representative GAD65/67- or nNOS-ir-positive neurons are indicated by blue arrows. Areas shown in Panels 1A & 2A were rephotographed after positioning of a continuous laser track (depicted in green) around a single GAD65/67-ir (Panel 1B, blue arrow) or nNOS-ir neuron (Panel 2B, blue arrow) & subsequent ejection of the encircled cell by laser pulse (Panels 1C & 2C). Note that this microdissection technique causes negligible destruction of surrounding tissue & minimal inclusion of adjacent tissue. Western blot analysis of triplicate cell lysate pools produced from immunolabeled GAD65/67 (Panel 1D) or nNOS (Panel 2D) neurons from Veh/Veh animals showed that these proteins are expressed in VMN neuron samples obtained by combinatory immunocytochemistry/laser-catapult microdissection. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416154636.jpg)
![Western Blot: nNOS Antibody [NBP1-39681] - Effects of ER alpha & ER beta Antagonists on NE Regulation of VMN GAD & nNOS Protein Expression. Micropunch-dissected VMN tissue was obtained from groups of ovariectomized, estradiol-replaced female rats pretreated by intra-VMN delivery of MPP, PHTPP, or vehicle (Veh) prior to NE administration for Western blot analysis of neuronal nitric oxide synthase (nNOS)—Panel 2A, F(5, 12) = 12.67, p < .0001—or glutamate decarboxylase65/67 (GAD)—Panel 2B, F(5, 12) = 7.13, p = .0003—protein expression. Data depict mean normalized protein optical density (O.D.) values ± SEM for groups of rats (n = 6 per group) infused with Veh (white bars) or NE (gray bars) after delivery of Veh (solid bars), MPP (diagonal-striped bars), or PHTPP (cross-hatched bars) administration. *p < .05; **p < .01; ***p < .001. MPP = 1,3-Bis(4-hydroxyphenyl)-4-methyl-5-[4-(2-piperidinylethoxy)phenol]-1H-pyrazole dihydrochloride; PHTPP = 4-[2-phenyl-5,7-bis(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl]phenol; NE = norepinephrine. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/32233668), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nbp1-39681_rabbit-nnos-pab-310202416175279.jpg)
![Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunocytochemistry-Immunofluorescence-NB100-724-img0004.jpg "Immunocytochemistry/Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - CTGF antibody was tested in U2OS cells with Dylight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and Dylight 550 (red).")
![Immunohistochemistry-Paraffin: CTGF/CCN2 Antibody [NB100-724] - Analysis of a FFPE tissue section of human lymph node using 1:200 dilution of CTGF/CCN2 antibody (NB100-724). The staining was developed using HRP labeled anti-rabbit secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin.](http://images.novusbio.com/fullsize/CTGF-CCN2-Antibody-Immunohistochemistry-Paraffin-NB100-724-img0005.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analysis of astrocyte reactivity, the cytoskeleton & migration rate following treatment with TGF-beta 2 & CCN2/CTGF. (A) GFAP immunoreactivity (green) is increased in murine ON astrocytes following TGF-beta 2 & CCN2/CTGF treatment. Nuclei are stained with Dapi (blue) (B) Western Blot experiments analyses of alpha -actinin protein synthesis in murine ON astrocytes after the treatment with 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 24 h. Densitometric analyses of Western Blot analyses shows the significant increase in alpha -actinin protein synthesis. Mean value of untreated cells (control) was set at 1. GAPDH was used to normalize protein intensity (n = 4; 50 ng CCN2/CTGF: *p = 0.029; 100 ng CCN2/CTGF: *p = 0.015; unpaired two-tailed t-test). (C) Scratch assay analyses show a significant increased migration rate for murine ON astrocytes after the treatment with ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF & 100 ng/ml CCN2/CTGF for 12 h. Mean value of migration rate of control cells was set to 100% (control: n = 15; TGF-beta 2: n = 12, **p = 0.008; 50 ng/ml CCN2/CTGF: n = 10, *p = 0.001; 100 ng/ml CCN2/CTGF: n = 4, **p = 0.0001). Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241683912.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415523931.jpg)
![Immunohistochemistry: CTGF/CCN2 Antibody [NB100-724] - GFAP expression & synthesis in the ON & ONH in a murine glaucoma model. (A) GFAP immunoreactivity in the glial lamina of 1-month (green, upper panel) & 2 months (green, middle & lower panel) old beta B1-CTGF1 mice compared to WT controls. Immunoreactivity of GFAP not altered in 1-month old TG & WT animals (green, upper panel). 2 month old beta B1-CTGF1 mice showed an increased GFAP immunoreactivity compared to WT control (green, middle panel). Lower panel shows a magnified detail of the middle panel. Nuclei are stained w/ Dapi (blue). (B) Schmatic illustration of the optic nerve. A depicts region in the glial lamina where cross sections obtained. ONH (unmyelinated part) & ON (myelinated part) used for molecular analysis. (C) Quantification of immunohistochemical staining of GFAP in the glial lamina is not altered in 1 month old TG & WT animals (WT: n = 5; TG: n = 4). GFAP immunoreactivity is increased in 2 month old TG animals compared to WT littermates (WT: n = 10, TG: n = 13; *p = 0.039; two-tailed t-test compared to oretical mean of 1 (normalized control)). Mean value of WT animals (control) set at 1. (D) RT-PCR analyses revealed no alteration in the Gfap mRNA expression in the ON of 1-month (WT: n = 7; TG: n = 5) & 2 month old beta B1-CTGF1 mice (WT: n = 15; TG: n = 16) compared to WT controls. In the ONH the Gfap mRNA expression is increased in the 2 month old TG compared to WT animals (WT: n = 6, TG: n = 5; *p = 0.04). The mRNA expression of Gfap is not altered in 1 month old animals (WT: n = 6, TG: n = 5). Mean value of WT animals (control) set at 1. RPL32 used to normalize mRNA expression. Data represented as mean ± SEM. PRL, Prelaminar region; PSL, Postlaminar region; ON, optic nerve; ONH, optic nerve head. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415535150.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Analyses of ECM components in murine ON astrocytes following treatment w/ TGF-beta 2 & CCN2/CTGF. (A) Immunocytochemical staining against fibronectin (green, upper panel) showed a markedly increase following the treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Immunocytochemical staining against tropoelastin (green, lower panel) showed a pronounced increase after treatment w/ 1 ng/ml TGF-beta 2 or 50 ng/ml CCN2/CTGF. Nuclei stained w/ Dapi (blue). (B) Real-time RT-PCR analyses shows an intense upregulation of collagen 3 alpha 1, tropoelastin & fibronectin mRNA in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3; TGF-beta 2 ***p = 0.0000004, 50 ngCTGF **p = 0.005, 100ngCTGF **p = 0.008; fibronectin: n = 6, TGF-beta 2 *p = 0.00004, 50 ng CTGF *p = 0.016, 100 ngCTGF *p = 0.05; elastin: n = 5, TGF-beta 2 *p = 0.026, 50 ng CTGF *0.04, 100 ng CTGF *p = 0.03). mRNA expression normalized to Gnb2l & mean value of control cells set at 1. (C) Western Blot analysis show an increase in protein synthesis of collagen 3 alpha 1, elastin & fibronectin in murine ON astrocytes after treatment w/ 1 ng/ml TGF-beta 2, 50 ng/ml CCN2/CTGF or 100 ng/ml CCN2/CTGF for 24 h compared to untreated control cells (collagen 3 alpha 1: n = 3, TGF-beta 2 *p = 0.03, 100 ngCTGF **p = 0.009; fibronectin: n = 5, **p = 0.005, 50 ngCTGF **p = 0.006, 100 ng CTGF *p = 0.02; tropoelastin: n = 5, TGF-beta 2 ***p = 0.0004, 50 ngCTGF **p = 0.002, 100 ngCTGF ***p = 0.00001). GAPDH & alpha -tubulin used to normalize protein synthesis & mean value of control cells set at 1. Right panel shows representative Western Blots for all three proteins. Data represented as mean ± SD. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-310202415532092.jpg)
![Immunocytochemistry/ Immunofluorescence: CTGF/CCN2 Antibody [NB100-724] - Increasing substratum stiffness causes alterations in murine ON astrocyte reactivity, actin cytoskeleton & CCN2/CTGF level. (A) Filamentous actin labeled by phalloidin (red, upper panel) is increased when murine ON astrocytes were cultured on substrates with higher stiffness (30 kPa, 60 kPa) compared to softer control (10 kPa). Increasing substratum stiffness leads to an enhanced formation of actin stress fibers. Immunoreactivity of CCN2/CTGF (green, middle panel) is markedly increased when murine ON astrocytes were grown on substrates with higher stiffness (30, 60 kPa) compared to softer control (10 kPa). Murine ON astrocytes show an enhanced GFAP protein synthesis (green, lower panel) when cultured on 30 or 60 kPa compared to 10 kPa. Nuclei were stained with Dapi (blue). (B) CCN2/CTGF protein synthesis is significantly increased in murine ON astrocytes grown on 60 kPa compared to 10 kPa (10 kPa: n = 5; 30 kPa: n = 5; 60 kPa: n = 5; *p = 0.04; unpaired two-tailed t-test). (C) Protein synthesis of GFAP (10 kPa: n = 6; 30 kPa: n = 6, **p = 0.005; 60 kPa: n = 4, *p = 0.04; unpaired two-tailed t-test) show an enhanced reactivity of murine ON astrocytes cultured on 30 kPa or 60 kPa compared to 10 kPa control. (D) Vimentin protein synthesis is significantly increased in murine ON astrocytes cultured on 60 kPa compared to 10 kPa (10 kPa: n = 4; 30 kPa: n = 4; 60 kPa: n = 3 ***p = 0.00002). Protein synthesis was normalized to alpha -tubulin & mean value of control (10 kPa) was set at 1. Data represented as mean ± SEM. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/35493079), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-724_rabbit-polyclonal-ctgf-ccn2-antibody-31020241612698.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0005.jpg "Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Action potentials were evoked with depolarizing current pulses. (A) Neuron from colonic specimen of non-treated patient fired 1 action potential in response to a depolarizing current. (A') Intracellular injection of carboxyfluorescein during recording confirmed Dogiel type I, uniaxonal morphology. (A")
![Immunohistochemistry-Paraffin: nNOS Antibody [NB100-858] - Staining of paraffin embedded Human Cortex. Steamed antigen retrieval with citrate buffer pH 6, AP-staining. Antibody at 2.5 ug/mL.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunohistochemistry-Paraffin-NB100-858-img0006.jpg)
![Flow Cytometry: nNOS Antibody [NB100-858] - Flow cytometric analysis of paraformaldehyde fixed Kelly cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (1 ug/mL). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/nNOS-Antibody-Flow-Cytometry-NB100-858-img0003.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Immunofluorescence analysis of paraformaldehyde fixed HeLa cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL), showing membrane, cytoplasmic and nuclear staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10 ug/mL) followed by Alexa Fluor 488 secondary antibody (2 ug/mL).](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: nNOS Antibody [NB100-858] - Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a-2d) and 7 (4a-4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a-1d) and 7 (3a-3d) days. Myenteric ganglia and neurons labeled with beta-Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of nNOS neurons (green) can be seen at both Days 3 and 7 after oxaliplatin treatment. Scale bar = 20 um. Image collected and cropped by CiteAb from the following publication (www.journal.frontiersin.org/article/10.3389/fnins.2013.00030/abstract) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/nNOS-Antibody-Immunocytochemistry-Immunofluorescence-NB100-858-img0004.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284925.jpg)
![Immunocytochemistry/ Immunofluorescence: nNOS Antibody [NB100-858] - (A) Wholemount preparations of the myenteric neurons in the distal colon segments following 3 (2a–2d) & 7 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 3 (1a–1d) & 7 (3a–3d) days. Myenteric ganglia & neurons labeled with beta -Tubulin Tuj1 (red), nuclei labeled with DAPI (blue) (arrows) can be seen within the ganglion (1b). Smooth muscle cells (asterisks) are also labeled with DAPI (1b). Significant increase in the proportion of NOS neurons (green) can be seen at both Days 3 & 7 after oxaliplatin treatment. Scale bar = 20 μm. (B) Wholemount preparations of the myenteric neurons in the distal colon segments following 14 (2a–2d) & 21 (4a–4d) days of repeated in vivo oxaliplatin administration compared to sham-treated animals at 14 (1a–1d) & 21 (3a–3d) days. The reduction in total number of neurons & increase in the proportion of NOS neurons was found at both Days 14 & 21 after oxaliplatin treatment. Scale bar = 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23486839), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-858_goat-polyclonal-nnos-antibody-310202416284920.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Human Fetal Heart. Antibody Dilution: 1.0ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0013.jpg "Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Human Fetal Heart. Antibody Dilution: 1.0ug/ml")
![Immunocytochemistry/Immunofluorescence: TGF-beta 1 Antibody [NBP1-80289] - Mouse kidney (red fluorescence). Nuclei were stained with DAPI (blue fluorescence). Working dilutions: 5-10 ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunocytochemistry-Immunofluorescence-NBP1-80289-img0008.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human Appendix FFPE tissue section stained with TGF-beta 1 antibody. IHC-P image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0011.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Antibody Titration: 0.2-1 ug/ml or 1:5000 to 1:1000 Dilution. SP2/0 cell lysate.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0010.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Mouse Spleen. Antibody Dilution: 1ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0012.jpg)
![Western Blot: TGF-beta 1 Antibody [NBP1-80289] - Sample Tissue: Mouse Pancreas. Antibody Dilution: 1ug/ml](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Western-Blot-NBP1-80289-img0014.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human Spleen Tissue, 5 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0007.jpg)
![Immunohistochemistry-Paraffin: TGF-beta 1 Antibody [NBP1-80289] - Human prostate cancer tissue was detected using RP/AEC red color stain. Working dilutions: 5-10 ug/ml.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Immunohistochemistry-Paraffin-NBP1-80289-img0009.jpg)
![Imaging Mass Cytometry: TGF-beta 1 Antibody [NBP1-80289] - Human bone marrow FFPE tissue sections. DNA in blue, TGF-beta 1 antibody staining in white. IMC image submitted by a verified customer review.](http://images.novusbio.com/fullsize/TGF-beta-1-Antibody-Imaging-Mass-Cytometry-NBP1-80289-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: Rabbit Polyclonal TGF-beta 1 Antibody [NBP1-80289] - Mice hepatocytes stained with TGF-beta 1 Antibody. Image from a verified customer review.](http://images.novusbio.com/fullsize/antibody/nbp1-80289_rabbit-polyclonal-tgf-beta-1-antibody-immunocytochemistry-immunofluorescence-25112024112535..png)
![Flow Cytometry: CD117/c-kit Antibody (2B8) [NB100-77477] - Detection of CD117/c-kit in Mouse Bone Marrow Cells by Flow Cytometry. Mouse bone marrow cells were stained with PE-conjugated Rat Anti-Mouse B220/CD45R (Catalog # FAB1217P) and Rat Anti-Mouse CD117/c-kit Monoclonal Antibody (Catalog # NB100-77477, top panel) or isotype control antibody (Catalog # MAB0061, bottom panel), followed by APC-conjugated Goat Anti-Rat IgG (Catalog # F0113).](http://images.novusbio.com/fullsize/CD117-c-kit-Antibody-2B8-Flow-Cytometry-NB100-77477-img0003.jpg "Flow Cytometry: CD117/c-kit Antibody (2B8) [NB100-77477] - Detection of CD117/c-kit in Mouse Bone Marrow Cells by Flow Cytometry. Mouse bone marrow cells were stained with PE-conjugated Rat Anti-Mouse B220/CD45R (Catalog # FAB1217P) and Rat Anti-Mouse CD117/c-kit Monoclonal Antibody (Catalog # NB100-77477, top panel) or isotype control antibody (Catalog # MAB0061, bottom panel), followed by APC-conjugated Goat Anti-Rat IgG (Catalog # F0113).")
![Flow Cytometry: CD117/c-kit Antibody (2B8) [NB100-77477] - Identification of CD117/c-kit expressing bone marrow cells.Double labeling of mouse bone marrow cells with anti-CD45 antibody and rabbit anti-CD117/c-kit antibody 2B8. Image collected and cropped by CiteAb from the following publication (//dx.plos.org/10.1371/journal.pone.0071798) licensed under a CC-BY license.](http://images.novusbio.com/fullsize/CD117-c-kit-Antibody-2B8-Flow-Cytometry-NB100-77477-img0004.jpg)
![Flow Cytometry: CD117/c-kit Antibody (2B8) [NB100-77477] - C57BL/6 bone marrow cells stained with 2B8 PE and CD11b FITC.](http://images.novusbio.com/fullsize/CD117-c-kit-Antibody-2B8-Flow-Cytometry-NB100-77477-img0002.jpg)
![Immunocytochemistry/Immunofluorescence: FLAP Antibody [NB300-891] - Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing strong endplasmic reticulum staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/FLAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-891-img0006.jpg "Immunocytochemistry/Immunofluorescence: FLAP Antibody [NB300-891] - Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing strong endplasmic reticulum staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).")
![Immunohistochemistry-Paraffin: FLAP Antibody [NB300-891] - Negative Control showing staining of paraffin embedded Human Spleen, with no primary antibody.](http://images.novusbio.com/fullsize/FLAP-Antibody-Immunohistochemistry-Paraffin-NB300-891-img0002.jpg)
![Flow Cytometry: FLAP Antibody [NB300-891] - Flow cytometric analysis of paraformaldehyde fixed MCF7 cells (blue line), permeabilized with 0.5% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (1ug/ml). IgG control: Unimmunized goat IgG (black line) followed by Alexa Fluor 488 secondary antibody.](http://images.novusbio.com/fullsize/FLAP-Antibody-Flow-Cytometry-NB300-891-img0007.jpg)
![Immunocytochemistry/Immunofluorescence: FLAP Antibody [NB300-891] - Immunofluorescence analysis of paraformaldehyde fixed MCF7 cells, permeabilized with 0.15% Triton. Primary incubation 1hr (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml), showing strong endplasmic reticulum staining. The nuclear stain is DAPI (blue). Negative control: Unimmunized goat IgG (10ug/ml) followed by Alexa Fluor 488 secondary antibody (2ug/ml).](http://images.novusbio.com/fullsize/FLAP-Antibody-Immunocytochemistry-Immunofluorescence-NB300-891-img0004.jpg)
![Immunohistochemistry-Paraffin: FLAP Antibody [NB300-891] - Staining of paraffin embedded Human Spleen. Heat induced antigen retrieval with citrate buffer pH 6, HRP-staining. Antibody at 6 ug/mL.](http://images.novusbio.com/fullsize/FLAP-Antibody-Immunohistochemistry-Paraffin-NB300-891-img0003.jpg)